Vraylar upsides
Vraylar may be used to treat adults having schizophrenia. It is licensed for the treatment of manic, mixed, or depressed episodes in individuals with bipolar I disorder. It can also be used in conjunction with antidepressants in people suffering from major depressive disorder (MDD).
Vraylar is an atypical antipsychotic, which means it is less likely to elicit extrapyramidal symptoms and tardive dyskinesia than previous antipsychotics. Vraylar use has been linked to a decrease in substance abuse in patients with bipolar I disorder.
Vraylar is less likely to produce blood sugar increases than other antipsychotics (such as Clozaril or Zyprexa). It is also less likely to cause blood cholesterol and lipid elevations than other atypical antipsychotics (such as Zyprexa or Seroquel).
Vraylar is generally well tolerated, has a good effect, and is less sedating than other atypical antipsychotics like Clozaril, Zyprexa, or Seroquel. Sedation was noted in 7% of Vraylar-treated individuals compared to 6% of placebo-treated patients in clinical trials.
It has a long half-life, which means that if a person misses a dose or takes it late, blood levels drop slowly. With a once-daily dosage, blood levels are also more stable. It hasn't been linked to as much weight gain as other antipsychotics.
